AU2002366200A1 - Sfcyr iib or sfcyr iii for the treatment of auto-immune diseases - Google Patents

Sfcyr iib or sfcyr iii for the treatment of auto-immune diseases

Info

Publication number
AU2002366200A1
AU2002366200A1 AU2002366200A AU2002366200A AU2002366200A1 AU 2002366200 A1 AU2002366200 A1 AU 2002366200A1 AU 2002366200 A AU2002366200 A AU 2002366200A AU 2002366200 A AU2002366200 A AU 2002366200A AU 2002366200 A1 AU2002366200 A1 AU 2002366200A1
Authority
AU
Australia
Prior art keywords
sfcyr
iib
iii
fcgammar
auto
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002366200A
Other languages
English (en)
Other versions
AU2002366200A8 (en
Inventor
Robert Huber
Uwe Jacob
Peter Sondermann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suppremol GmbH
Max Planck Gesellschaft zur Foerderung der Wissenschaften
Original Assignee
Suppremol GmbH
Max Planck Gesellschaft zur Foerderung der Wissenschaften
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suppremol GmbH, Max Planck Gesellschaft zur Foerderung der Wissenschaften filed Critical Suppremol GmbH
Publication of AU2002366200A8 publication Critical patent/AU2002366200A8/xx
Publication of AU2002366200A1 publication Critical patent/AU2002366200A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2002366200A 2001-11-22 2002-11-21 Sfcyr iib or sfcyr iii for the treatment of auto-immune diseases Abandoned AU2002366200A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10157290A DE10157290A1 (de) 2001-11-22 2001-11-22 Pharmazeutische Zusammensetzung enthaltend sFcRgamma IIb oder sFcRgamma III
DE10157290.5 2001-11-22
PCT/EP2002/013080 WO2003043648A2 (de) 2001-11-22 2002-11-21 Sfcyr iib oder sfcyr iii für die behandlung von autoimmunkrankheiten

Publications (2)

Publication Number Publication Date
AU2002366200A8 AU2002366200A8 (en) 2003-06-10
AU2002366200A1 true AU2002366200A1 (en) 2003-06-10

Family

ID=7706571

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002366200A Abandoned AU2002366200A1 (en) 2001-11-22 2002-11-21 Sfcyr iib or sfcyr iii for the treatment of auto-immune diseases

Country Status (10)

Country Link
US (2) US20050002924A1 (enExample)
EP (1) EP1446139B1 (enExample)
JP (1) JP5414959B2 (enExample)
AT (1) ATE409045T1 (enExample)
AU (1) AU2002366200A1 (enExample)
CA (1) CA2506068C (enExample)
CO (1) CO5590936A2 (enExample)
DE (2) DE10157290A1 (enExample)
ES (1) ES2309238T3 (enExample)
WO (1) WO2003043648A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1709073E (pt) * 2003-11-26 2011-09-29 Max Planck Gesellschaft Substância que se liga ao receptor fc iib de igg humano (fcgamariib)
US10028998B2 (en) * 2012-10-30 2018-07-24 Suppremol Gmbh Method for treating an inflammatory disease and/or an autoimmune disease with a soluble FcγRIIb
US10669324B2 (en) 2012-10-30 2020-06-02 Suppremol Gmbh Vector encoding an Fc gamma receptor IIB protein and composition of the encoded protein
EP2914623B1 (en) 2012-10-30 2016-12-28 SuppreMol GmbH A pharmaceutical composition for use in treating or preventing either one or both of an inflammatory disease and an autoimmune disease
AU2012244302B2 (en) * 2012-10-31 2014-08-21 Suppremol Gmbh A method for treating or preventing either one or both of an inflammatory disease and an autoimmune disease
EP2796144A1 (en) 2013-04-26 2014-10-29 SuppreMol GmbH Highly concentrated Formulations of soluble Fc receptors
EP2833139A1 (en) * 2013-08-01 2015-02-04 SuppreMol GmbH In vitro method for determining the stability of compositions comprising soluble Fc gamma receptor(s)
EP2837637A1 (en) 2013-08-16 2015-02-18 SuppreMol GmbH Novel anti-FcyRIIB IgG-type antibody
CN105873600B (zh) 2013-10-16 2019-11-05 苏伯利莫尔公司 用于自身免疫性大疱病治疗的可溶性Fcγ受体
JP6893223B2 (ja) * 2013-10-16 2021-06-23 ズプレモル ゲーエムベーハー 医薬品組成物およびキット
JP2018050616A (ja) 2016-09-23 2018-04-05 東ソー株式会社 改良型組換えＦｃγＲＩＩ

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1053255A4 (en) * 1998-02-06 2003-01-02 Ilexus Pty Ltd THREE-DIMENSIONAL STRUCTURES AND MODELS OF Fc RECEPTORS, AND USES THEREOF
EP1006183A1 (en) * 1998-12-03 2000-06-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Recombinant soluble Fc receptors
EP1201681A1 (en) * 2000-10-30 2002-05-02 Millennium Pharmaceuticals, Inc. "Fail" molecules and uses thereof

Also Published As

Publication number Publication date
CA2506068C (en) 2011-09-20
US20080214459A1 (en) 2008-09-04
AU2002366200A8 (en) 2003-06-10
CA2506068A1 (en) 2003-05-30
WO2003043648A3 (de) 2004-01-08
WO2003043648A2 (de) 2003-05-30
DE50212814D1 (de) 2008-11-06
ES2309238T3 (es) 2008-12-16
US20050002924A1 (en) 2005-01-06
CO5590936A2 (es) 2005-12-30
JP5414959B2 (ja) 2014-02-12
JP2005515981A (ja) 2005-06-02
ATE409045T1 (de) 2008-10-15
DE10157290A1 (de) 2003-06-05
EP1446139A2 (de) 2004-08-18
EP1446139B1 (de) 2008-09-24

Similar Documents

Publication Publication Date Title
SI1480961T1 (sl) Inhibitorji dpiv na osnovi glutaminila
MXPA04005376A (es) Composiciones farmaceuticas y sus usos.
SE9702001D0 (sv) Novel compounds
BR0313059B8 (pt) composto, e, composição farmacêutica
GEP20104922B (en) Antibodies to m-csf
AU2002366200A1 (en) Sfcyr iib or sfcyr iii for the treatment of auto-immune diseases
EP1354598A3 (en) Therapeutic uses of BR43X2 soluble receptors
IL181473A (en) Antibodies @ people @ against @@@ beta @@ preparations that include them and use them
UA29494C2 (uk) Гуманізовані антитіла, способи їх продукування, спосіб лікування хвороби крона, спосіб лікування розсіяного склерозу, фармацевтична композиція
GEP20084484B (en) Antibodies to insulin-like growth factor i receptor
ATE423769T1 (de) Fluor- und sulfonylaminohaltige, 3,6- disubstituierte azabicyclo 3.1.0 hexanderivate als muscarinrezeptorantagonisten
AU2002359727A1 (en) Fused cyclic modulators of nuclear hormone receptor function
EP1461313A4 (en) INHIBITORS OF HUMAN ADAM-10
WO2004087073A3 (en) Treatment of demyelinating conditions
WO2002081745A3 (en) Genes involved in osteogenesis, and methods of use
AU1022999A (en) 1,3-dihydroxy-20,20-dialkyl-vitamin d3 analogs
MXPA04000446A (es) 4-aminociclohexanoles sustituidos.
MY134019A (en) Aryl oxime-piperazines useful as ccr5 antagonists
SI1765337T1 (sl) Kombinacija tenofovirja, ritonavirja in TMC114
AU7525398A (en) Inhibitors for urokinase receptor
AU703179B2 (en) Recombinant canine gastric lipase and pharmaceutical compositions
MXPA04001986A (es) Composiciones y metodos para el tratamiento de enfermedades relacionadas a la inmunidad.
WO2004043397A3 (en) Compositions and methods for the treatment of rheumatoid arthritis
WO2004089302A3 (en) Posh polypeptides, complexes and related methods
AU7079300A (en) Compositions and methods for the treatment of immune related diseases

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase